Effective October 1, 2015, Acino Pharma, an international pharmaceutical company headquartered in Switzerland, acquires Pharma Start, the 9th largest local...
Acino’s rivastigmine patch is the first generic alternative to the originator product making the medical treatment of Alzheimer’s more affordable...
Acino announces the achievement of another judicial success in the ongoing German intellectual property litigation proceedings regarding its generic rivastigmine...
Acino is proud to be the recipient of the Frost & Sullivan “2014 European Pharmaceutical Drug Delivery Enabling Technology Leadership...
After the successful completion of the public tender offer of Pharma Strategy Partners for Acino Holding AG on December 12,...
With decision dated June 26, 2014, the Cantonal court of Basel-Landschaft has admitted the claim of Pharma Strategy Partners GmbH,...
After the successful completion of the tender offer of Pharma Strategy Partners for Acino Holding AG (Acino), SIX Exchange Regulation...
On December 20, 2013, SIX Swiss Exchange (SIX) approved Acino Holding AG’s request for the delisting of its registered shares....